The present invention relates to the CGRP antagonists of general formula ##STR00001## wherein A, X, D, E, G, M, Q and R.sup.1 to R.sup.3 are defined as in claim 1, the tautomers, the diastereomers, the enantiomers, the hydrates thereof, the mixtures thereof and the salts thereof and the hydrates of the salts, particularly the physiologically acceptable salts thereof with inorganic or organic acids, pharmaceutical compositions containing these compounds, the use thereof and processes for the preparation thereof.